BioXcel Therapeutics secures an 11-day lifeline as its liquidity covenant is halved to $3M

summarizeSummary

BioXcel Therapeutics amended its credit agreement again, extending the deadline to August 21, 2026 to finalize a transaction that repays its debt or provides alternative capital, while reducing the minimum cash requirement to $3 million.

check_boxKey Events · Financing and Capital Events · BTAI

• Deadline Extended to August 21

  The Twelfth Amendment extends the deadline to enter into definitive agreements for an Acceptable Transaction from August 10 to August 21, 2026, giving the company 11 more days to avoid default.

• Liquidity Covenant Halved

  The minimum cash liquidity covenant was reduced from $6.25 million to $3.0 million, providing immediate relief but reflecting the company's dwindling cash reserves.

• Third Consecutive Amendment

  This is the third amendment in recent months (following the Tenth and Eleventh Amendments), indicating ongoing difficulty in securing a transaction acceptable to lenders.

• Distressed Financial Position

  With a market cap of $28.7 million and a stock price of $0.95, the company is under severe financial pressure, and failure to meet the new deadline could lead to a default under the credit agreement.

auto_awesomeAnalysis · BTAI · Life Sciences

BioXcel Therapeutics entered a Twelfth Amendment to its credit agreement with Oaktree, pushing the deadline to secure a definitive transaction to August 21, 2026, and slashing the minimum cash liquidity requirement from $6.25 million to $3.0 million. This marks the third consecutive amendment extending the debt resolution deadline, signaling that the company is struggling to find an acceptable deal. While the reduced liquidity covenant provides immediate breathing room, it also underscores the severity of the cash crunch. With a market cap of only $28.7 million and a stock price below $1, the company is in a distressed state, and failure to meet the new deadline could trigger a default.